{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:04:49Z","timestamp":1784739889395,"version":"3.55.0"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,12,25]]},"DOI":"10.1248\/bpb.b25-00610","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T22:23:50Z","timestamp":1766615030000},"page":"1978-1985","source":"Crossref","is-referenced-by-count":2,"title":["DNA-Damaging Agents Induce PD-L1 Expression through the Src-STAT1-IRF1 Pathway"],"prefix":"10.1248","volume":"48","author":[{"given":"Yuri","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soshi","family":"Nishibu","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nohara","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iimi","family":"Onuma","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930\u20130194, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. <i>Science<\/i>, <b>271<\/b>, 1734\u20131736 (1996).","DOI":"10.1126\/science.271.5256.1734"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Topalian SL, Hodi FS, Brahmer JR, <i>et al<\/i>. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. <i>N. Engl. J. Med.<\/i>, <b>366<\/b>, 2443\u20132454 (2012).","DOI":"10.1056\/NEJMoa1200690"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Brahmer JR, Tykodi SS, Chow LQM, <i>et al<\/i>. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. <i>N. Engl. J. Med.<\/i>, <b>366<\/b>, 2455\u20132465 (2012).","DOI":"10.1056\/NEJMoa1200694"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Nathan P, Hassel JC, Rutkowski P, <i>et al<\/i>. Overall survival benefit with tebentafusp in metastatic uveal melanoma. <i>N. Engl. J. Med.<\/i>, <b>385<\/b>, 1196\u20131206 (2021).","DOI":"10.1056\/NEJMoa2103485"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Shin DS, Zaretsky JM, Escuin-Ordinas H, <i>et al<\/i>. Primary Resistance to PD-1 blockade mediated by JAK1\/2 mutations. <i>Cancer Discov.<\/i>, <b>7<\/b>, 188\u2013201 (2017).","DOI":"10.1158\/2159-8290.CD-16-1223"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Zaretsky JM, Garcia-Diaz A, Shin DS, <i>et al<\/i>. Mutations associated with acquired resistance to PD-1 blockade in melanoma. <i>N. Engl. J. Med.<\/i>, <b>375<\/b>, 819\u2013829 (2016).","DOI":"10.1056\/NEJMoa1604958"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Wu Q, Zhao Y, Sun Y, Yan X, Wang P. MiR-375 inhibits IFN-\u03b3-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2\/STAT1 signaling. <i>Oncol. Rep.<\/i>, <b>39<\/b>, 1461\u20131468 (2018).","DOI":"10.3892\/or.2018.6177"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DSM, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. <i>Cell<\/i>, <b>167<\/b>, 1540\u20131554.e12 (2016).","DOI":"10.1016\/j.cell.2016.11.022"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ, Ritz J. Interferon-\u03b3-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. <i>OncoImmunology<\/i>, <b>4<\/b>, e1008824 (2015).","DOI":"10.1080\/2162402X.2015.1008824"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. <i>Cell Rep.<\/i>, <b>19<\/b>, 1189\u20131201 (2017).","DOI":"10.1016\/j.celrep.2017.04.031"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Moon JW, Kong SK, Kim BS, Kim HJ, Lim H, Noh K, Kim Y, Choi JW, Lee JH, Kim YS. IFN\u03b3 induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma. <i>Sci. Rep.<\/i>, <b>7<\/b>, 17810 (2017).","DOI":"10.1038\/s41598-017-18132-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, Ring AM, Weissman IL, Maute RL. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. <i>Nat. Immunol.<\/i>, <b>19<\/b>, 76\u201384 (2018).","DOI":"10.1038\/s41590-017-0004-z"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, Choi IH. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-\u03b3-induced upregulation of B7-H1 (CD274). <i>FEBS Lett.<\/i>, <b>580<\/b>, 755\u2013762 (2006).","DOI":"10.1016\/j.febslet.2005.12.093"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yokoyama S, Takahashi A, Kikuchi R, Nishibu S, Lo JA, Hejna M, Moon WM, Kato S, Zhou Y, Hodi FS, Song JS, Sakurai H, Fisher DE, Hayakawa Y. SOX10 regulates melanoma immunogenicity through an IRF4-IRF1 Axis. <i>Cancer Res.<\/i>, <b>81<\/b>, 6131\u20136141 (2021).","DOI":"10.1158\/0008-5472.CAN-21-2078"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nguyen MT, Kikuchi R, Nishibu S, Zhou Y, Moritake H, Nakamura T, Outani H, Hayashi R, Sakurai H, Yokoyama S. HDAC inhibitors induce HLA class I molecules through the SOX10-IRF1 axis in clear cell sarcoma cells. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 1913\u20131919 (2024).","DOI":"10.1248\/bpb.b24-00640"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Takahashi K, Takahashi A, Takahashi N, Zhou Y, Sakurai H, Yokoyama S. Proteasome inhibition induces IRF1 downstream molecules independently of JAK activity in cancers. <i>Biol. Pharm. Bull.<\/i>, <b>48<\/b>, 864\u2013871 (2025).","DOI":"10.1248\/bpb.b25-00006"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Sato H, Niimi A, Yasuhara T, Permata TBM, Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, Yoshimoto Y, Held KD, Suzuki Y, Kono K, Miyagawa K, Nakano T, Shibata A. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. <i>Nat. Commun.<\/i>, <b>8<\/b>, 1751 (2017).","DOI":"10.1038\/s41467-017-01883-9"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Zander DY, Burkart SS, W\u00fcst S, Magalh\u00e3es VG, Binder M. Cooperative effects of RIG-I-like receptor signaling and IRF1 on DNA damage-induced cell death. <i>Cell Death Dis.<\/i>, <b>13<\/b>, 364 (2022).","DOI":"10.1038\/s41419-022-04797-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Eshima S, Yokoyama S, Abe T, Hayakawa Y, Saiki I. Multi-pathway cellular analysis on crude natural drugs\/herbs from Japanese Kampo formulations. <i>PLOS ONE<\/i>, <b>10<\/b>, e0128872 (2015).","DOI":"10.1371\/journal.pone.0128872"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. <i>Nat. Methods.<\/i>, <b>11<\/b>, 783\u2013784 (2014).","DOI":"10.1038\/nmeth.3047"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Schreiber E, Matthias P, M\u00fcller MM, Schaffner W. Rapid detection of octamer binding proteins with \u201cmini-extracts\u201d, prepared from a small number of cells. <i>Nucleic Acids Res.<\/i>, <b>17<\/b>, 6419 (1989).","DOI":"10.1093\/nar\/17.15.6419"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Larroquette M, Domblides C, Lefort F, Lasserre M, Quivy A, Sionneau B, Bertolaso P, Gross-Goupil M, Ravaud A, Daste A. Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: a review. <i>Eur. J. Cancer<\/i>, <b>158<\/b>, 47\u201362 (2021).","DOI":"10.1016\/j.ejca.2021.09.013"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. <i>Nat. Rev. Clin. Oncol.<\/i>, <b>17<\/b>, 725\u2013741 (2020).","DOI":"10.1038\/s41571-020-0413-z"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Girdlestone J, Isamat M, Gewert D, Milstein C. Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>90<\/b>, 11568\u201311572 (1993).","DOI":"10.1073\/pnas.90.24.11568"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Doi T, Ishikawa T, Okayama T, Oka K, Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Naito Y, Itoh Y. The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. <i>Oncol. Rep.<\/i>, <b>37<\/b>, 1545\u20131554 (2017).","DOI":"10.3892\/or.2017.5399"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Frank DA, Mahajan S, Ritz J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. <i>Nat. Med.<\/i>, <b>5<\/b>, 444\u2013447 (1999).","DOI":"10.1038\/7445"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Chang YJ, Holtzman MJ, Chen CC. Differential role of Janus family kinases (JAKs) in interferon-\u03b3 -induced lung epithelial ICAM-1 expression: involving protein interactions between JAKs, phospholipase C\u03b3, c-Src, and STAT1. <i>Mol. Pharmacol.<\/i>, <b>65<\/b>, 589\u2013598 (2004).","DOI":"10.1124\/mol.65.3.589"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Uchihara Y, Permata TBM, Sato H, Kawabata-Iwakawa R, Katada S, Gu W, Kakoti S, Yamauchi M, Kato R, Gondhowiardjo S, Hosen N, Yasuhara T, Shibata A. DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production. <i>Mol. Cell.<\/i>, <b>82<\/b>, 2557\u20132570.e7 (2022).","DOI":"10.1016\/j.molcel.2022.04.030"},{"key":"29","unstructured":"29) Pu M, Akhand AA, Kato M, Hamaguchi M, Koike T, Iwata H, Sabe H, Suzuki H, Nakashima I. Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation. <i>Oncogene<\/i>, <b>13<\/b>, 2615\u20132622 (1996). &lt;https:\/\/pubmed.ncbi.nlm.nih.gov\/9000135\/&gt;."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Giannoni E, Buricchi F, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. <i>Mol. Cell. Biol.<\/i>, <b>25<\/b>, 6391\u20136403 (2005).","DOI":"10.1128\/MCB.25.15.6391-6403.2005"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00610\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:27:05Z","timestamp":1766806025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/12\/48_b25-00610\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00610","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"article-number":"b25-00610"}}